In a press release (12 December 2001), researchers with MetaPhore Pharmaceuticals, Inc. of St. Louis, MO and the University of Messina (Italy) announced that the companyís artificial enzyme significantly reduced the extent and severity of inflammation and tissue damage to the intestinal wall in an animal model of colitis. The study suggests that MetaPhoreís artificial molecule, which mimics the action of the enzyme superoxide dismutase (SOD), may have potential in the treatment of inflammatory bowel disease (IBD), a group of disorders that cause inflammation or ulceration of the digestive tract.
Previous studies on the use of the artificial enzymes were covered here in July 2001.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.